Therapeutic Value of EGFR Inhibition in CRC and NSCLC: 15 years of Clinical Evidence

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2016 Nov 16

PMID 27843640

Citations 55

Authors

Teresa Troiani

Stefania Napolitano

Carminia Maria Della Corte

Giulia Martini

Erika Martinelli

Floriana Morgillo

Fortunato Ciardiello

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, and is one of the most important targets for biological therapy, especially for non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC). In the past 15 years, several EGFR antagonists have been approved for the treatment of NSCLC and metastatic CRC (mCRC). To optimise the use of anti-EGFR agents in clinical practice, various clinical and molecular biomarkers have been investigated, thus moving their indication from unselected to selected populations. Nowadays, anti-EGFR drugs represent a gold-standard therapy for metastatic NSCLC harbouring activating mutation and for wild-type mCRC. Their clinical efficacy is limited by the presence of intrinsic resistance or the onset of acquired resistance. In this review, we provide an overview of the antitumour activity of EGFR inhibitors in NSCLC and CRC and of mechanisms of resistance, focusing on the development of a personalised approach through 15 years of preclinical and clinical research.

Citing Articles

First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?.

Airoldi M, Bartolini M, Fazio R, Farinatti S, Dapra V, Santoro A Curr Oncol Rep. 2024; 26(11):1489-1501.

PMID: 39392559 DOI: 10.1007/s11912-024-01601-x.

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect.

Crook Z, Sevilla G, Young P, Girard E, Phi T, Howard M Nat Commun. 2024; 15(1):8731.

PMID: 39384759 PMC: 11464628. DOI: 10.1038/s41467-024-52975-2.

CYpHER: Catalytic extracellular targeted protein degradation with high potency and durable effect.

Crook Z, Sevilla G, Young P, Girard E, Phi T, Howard M bioRxiv. 2024; .

PMID: 38712232 PMC: 11071310. DOI: 10.1101/2024.02.21.581471.

Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer.

Li Y, Wang B, Yang W, Ma F, Zou J, Li K Nat Commun. 2024; 15(1):980.

PMID: 38302471 PMC: 10834432. DOI: 10.1038/s41467-024-44911-1.

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.

Li F, Yu J, Pan T, Feng H, Li J, Yu B Adv Sci (Weinh). 2023; 10(34):e2303091.

PMID: 37863665 PMC: 10700682. DOI: 10.1002/advs.202303091.

References

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L . Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015; 21(9):2157-66. DOI: 10.1158/1078-0432.CCR-14-2821. View

Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M . Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012; 18(2):221-3. DOI: 10.1038/nm.2609. View

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C . Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2014; 26(1):13-21. DOI: 10.1093/annonc/mdu378. View

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Rosello S . Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015; 5(6):598-609. DOI: 10.1158/2159-8290.CD-14-1432. View

Van Cutsem E, Lenz H, Kohne C, Heinemann V, Tejpar S, Melezinek I . Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015; 33(7):692-700. DOI: 10.1200/JCO.2014.59.4812. View

Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C . Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol. 2016; 27(6):1055-1061. DOI: 10.1093/annonc/mdw136. View

10.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C . Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5):587-94. DOI: 10.1016/j.ejca.2015.01.054. View

11.

Troiani T, Napolitano S, Martini G, Martinelli E, Cardone C, Normanno N . Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clin Cancer Res. 2015; 21(18):4153-64. DOI: 10.1158/1078-0432.CCR-15-0211. View

12.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

13.

Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel N . Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol. 2013; 35(2):1041-9. DOI: 10.1007/s13277-013-1138-8. View

14.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P . PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31(23):2895-902. DOI: 10.1200/JCO.2012.47.1102. View

15.

Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda L, Costantino S . Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res. 2013; 19(24):6751-65. DOI: 10.1158/1078-0432.CCR-13-0423. View

16.

Godin-Heymann N, Bryant I, Rivera M, Ulkus L, Bell D, Riese 2nd D . Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007; 67(15):7319-26. PMC: 2882853. DOI: 10.1158/0008-5472.CAN-06-4625. View

17.

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F . Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25(12):1545-52. DOI: 10.1200/JCO.2005.05.1474. View

18.

Baselga J, Pfister D, Cooper M, Cohen R, Burtness B, Bos M . Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18(4):904-14. DOI: 10.1200/JCO.2000.18.4.904. View

19.

Bivona T, Hieronymus H, Parker J, Chang K, Taron M, Rosell R . FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011; 471(7339):523-6. PMC: 3541675. DOI: 10.1038/nature09870. View

20.

Pedersen M, Jacobsen H, Koefoed K, Hey A, Pyke C, Haurum J . Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010; 70(2):588-97. DOI: 10.1158/0008-5472.CAN-09-1417. View